Adam D. Levy, Chief Financial Officer at Acrivon Therapeutics, sold ACRV on Aug 4, 2026
Data as of Oct 16
- Traded
- Aug 4, 2026
- Disclosed
- Aug 6, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ACRV since disclosure
−3.0%
after the sale
Similar stocks (XLV) since disclosure
+7.5%
XLV — its sector index fund
Change in closing price from Aug 6, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.